Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Zhen Shi, Steven J. Isakoff(Harvard University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Isabel Calvo(Centro Oncológico de Galicia), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Rosa I. Gallagher(George Mason University), Debra A. Pratt(Cleveland Clinic), Eva Ciruelos(Hospital Universitario 12 De Octubre), Patricia Villagrasa, Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Cristina Saura(Vall d'Hebron Hospital Universitari), José Luís Passos‐Coelho, Małgorzata Nowicka(University of Zurich), Matthew Wongchenko, Jay Andersen(Hvidovre Hospital), Begoña Bermejo(Hospital Clínico Universitario de Valencia)
Cited by 54
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k